
    
      This is a single arm clinical trial conducted in China. The purpose of this study is to
      assess the efficacy and safety of Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per
      cycle) combined with Docetaxel (75mg/m2 IV d1) in the treatment of wild-type advanced
      non-squamous non small cell lung cancer patients with progression after immunotherapy plus
      chemotherapy as first-line treatment. After being informed about the study and potential
      risks, all patients giving written informed consent will undergo a 4-week screening period to
      determine eligibility for study entry. The expected sample size is 42.
    
  